Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Drug interactions and pharmacokinetics news

Show

From To
Taking Birth Control With HIV Treatment or PrEP Is Largely OK

Women taking various forms of hormonal contraceptives can likely combine them safely with antiretrovirals (ARVs), whether as HIV treatment or in the form of Truvada (tenofovir disoproxil fumarate/emtricitabine) as pre-exposure prophylaxis (PrEP) against the virus. The one ARV that may be problematic to combine with such forms of birth control is Sustiva (efavirenz), which is included in Atripla (efavirenz/tenofovir disoproxil fumarate/emtricitabine).

Published
30 May 2017
From
Poz
Unexpected side effects with generic abacavir – and potential for rare reactions to other generic ARVs

Several anecdotal reports of mouth ulcers have recently been reported in people switching to generic abacavir in the UK. This should highlight awareness of the potential of likely-rare new side effects, even when both formulations have been approved as bioequivalent.

Published
23 May 2017
From
HIV i-Base
Glecaprevir/pibrentasvir for hepatitis C can be safely administered with common antiretrovirals

AbbVie's investigational glecaprevir/pibrentasvir treatment for hepatitis C is not expected to interact with or require dose adjustment when taken with commonly used antiretroviral regimens, offering a new option

Published
10 March 2017
By
Liz Highleyman
New nano approach could cut dose of leading HIV treatment in half

Successful results of a University of Liverpool-led trial that utilised nanotechnology to improve drug therapies for HIV patients has been presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, a leading annual conference of HIV research, clinical practice and progress.

Published
21 February 2017
From
University of Liverpool press release
Gates Foundation to Invest Up to $140 Million in HIV Prevention Device

The tiny implantable drug pump is being developed by Intarcia Therapeutics Inc. It can hold six or 12 months’ supply of medicine and is designed to deliver microdoses continuously to patients, ensuring they stay on the treatment.

Published
30 December 2016
From
Wall Street Journal
What's at Stake in Trump's America? HIV Community Leaders Share Their Opinions

By Election Day Nov. 8, after an eventful primary season and a noxious election cycle, it seemed that most HIV advocates were ready to get to work with a soon-to-be President-elect Hillary Clinton's soon-to-be administration, to continue the pioneering work activists forged under President Obama in addressing HIV in the U.S. Then the unthinkable happened. In the wee hours of Nov. 9, Donald J. Trump was declared the president-elect of the United States.

Published
21 November 2016
From
The Body
The ‘long tail’ problem: injected-PrEP trial will be extended due to persistence of drug in companion study

A study presented at last month’s HIV Research for Prevention (HIVR4P) conference in Chicago shows that in a minority of subjects who were given an experimental

Published
11 November 2016
By
Gus Cairns
Tests of online PrEP purchases by London clinic find no fakes, and adequate drug levels

A sexual health clinic in central London that offered to test drug levels in users of tenofovir/emtricitabine pre-exposure prophylaxis (PrEP) who had bought it online found adequate

Published
26 October 2016
By
Gus Cairns
Doctors in Netherlands observe higher than expected dolutegravir treatment discontinuation rate

Almost one in seven people in a Dutch clinic population stopped treatment with the HIV integrase inhibitor dolutegravir because of side-effects, investigators from the Netherlands report in

Published
13 October 2016
By
Michael Carter
Evidence that “on-demand” PrEP taken before and after sex can prevent HIV

How many doses of Truvada-based PrEP (pre-exposure prophylaxis) are needed to provide adequate protection against HIV? Might it be possible to take PrEP only before and after sex—instead of every day?

Published
12 September 2016
From
BETA blog
← First12345...21Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.